Abstract. Aim of the study was to clarify the relationship between metformin-induced vitamin B12 (B12) deficiency, hyperhomocysteinemia and vascular complications in patients with type 2 diabetes. Serum B12 concentrations, homocysteine plasma levels, the presence of retinopathy and history of macroangiopathy (stroke or coronary heart disease) were analyzed in patients without renal dysfunction (serum creatinine<115 µmol/L). Firstly, B12 status was analyzed in 62 consecutive metformin-treated patients. Secondly, the relationship between B12, homocysteine and vascular complications was analyzed in 46 metformin-treated and 38 age-and sex-matched non-metformin-treated patients. Among the 62 consecutive metformin-treated patients, B12 was deficient (<150 pmol/L) in 8 (13%) and borderline-deficient (150-220 pmol/L) in 18 (29%): the larger the metformin dosage, the lower the B12 (P=0.02, Spearman's ρ=-0.30). There were independent correlations between metformin use and B12 lowering (P = 0.02, r = -0.25), and B12 lowering and elevation of homocysteine (P<0.01, r =-0.34). Elevation of homocysteine was a risk for retinopathy (P =0.02, OR 1.26, 95%CI 1.04-1.52). There was no significant relation between homocysteine and macroangiopathy. Correlation between B12 and homocysteine was stronger in metformin-treated (P<0.01, r =-0.48) than non-metformin-treated (P=0.04, r = -0.38) patients. In ten B12 deficient patients, B12 supplementation (1,500 µg/day) for 2.2±1.0 months with continued use of metformin raised B12 levels: 152±42 and 299±97 pmol/L before and after treatment, respectively (P<0.01). Metformininduced B12 lowering in diabetes was associated with elevation of homocysteine, and hyperhomocysteinemia was independently related to retinopathy. Metformin-induced B12 deficiency was correctable with B12 supplementation.
). There was no significant correlation between the duration of metformin treatment and B12. Among 38 non-metformin-treated patients (see below), B12 deficiency (<150 pmol/L) was present in 3 (8%) and borderline-deficiency (150-220 pmol/L) in 5 (13%). Prevalence of abnormal (deficiency and borderline-deficiency combined) serum B12 was significantly lower in the non-metformin-treated patients than in the 62 metformin-treated patients (8/38 vs 26/62, P = 0.049).
Relationship between metformin use, B12, HC and vascular complications
Relationship between metformin use, B12, HC, HC to B12 molar ratio and vascular complications was analyzed in 84 patients: 46 metformin-treated patients and 38 ageand sex-matched non-metformin-treated patients. The 46 meformin-treated patients were randomly selected from the entire 62 metformin users. In this subgroup of metformin users (N = 46), the number of subjects with B12 deficiency was 6 (13%) and those with borderline-deficiency was 9 (20%), and the prevalence of subjects with abnormal serum B12 (deficiency and borderline-deficiency combined) was not significantly different between this group and the entire 62 metformin users (15/46 vs 26/62, P = 0.42). However, the correlation between metformin dose and serum B12 (P= 0.20) and plasma HC (P = 0.97) was not statistically significant. Serum B12 level was significantly lower in the metformin than in the non-metformin groups (Table 1) . Plasma HC concentration was slightly but insignificantly higher in the former than in the latter: HC to B12 molar ratio was significantly higher in the former. BMI was greater in the former than in the latter group.
were excluded, so that the analysis was performed in 38 of the non-metformin-treated patients.
Analysis
The presence of diabetic retinopathy was diagnosed after dilation of the pupils by ophthalmologists who were unaware of the B12 and HC data. Any history of macroangiopathic events, i.e., coronary heart disease and/or stroke necessitating hospitalization, was recorded. Information relating to the duration of diabetes was obtained by questioning the patients. Any use of proton pump inhibitors or H2 blockers was also recorded because it can be associated with B12 deficiency [13] . HbA1c was determined by HPLC (Arkray, GA-8170). B12 and HC were determined by HPLC and chemiluminescent enzyme immunoassay, respectively, at a clinical laboratory (SRL, Tokyo). Patients were diagnosed as B12 deficient with a serum B12 concentration of <150 pmol/L and as borderline-deficient with 150-220 pmol/L [4] . Plasma HC ≥10 µmol/L was regarded as hyperhomocysteinemia [9, 14] . The estimated glomerular filtration rate (eGFR) was calculated using a formula developed for Japanese subjects [15] .
Statistics
Statistical analysis was performed using SPSS version 21 and P <0.05 was considered significant. Fisher's exact test, Mann-Whitney U test, Wilcoxon's signed rank test, Spearman's rank correlation, partial correlation analysis, and logistic regression analysis were used as needed. Five missing values were regarded as "absent", and pairwise omission was selected in the partial correlation. The values for B12, HC, HC/B12 molar ratio, HbA1c and duration of diabetes were log transformed to obtain normal distribution in the correlation analysis.
Results

Status of B12 in metformin-treated patients
In the 62 consecutive metformin-treated patients (male/female 49/13, mean age 62 yrs, HbA1c 7.5% (58 mmol/mol), metformin dosage 1.1 g/day and duration of metformin therapy 2.9 yrs), B12 deficiency (<150 pmol/L) was present in 8 (13%) and borderline-deficiency (150-220 pmol/L) in 18 (29%). The metformin dosage was lowest in the normal B12 group, intermediate in the borderline-deficiency group and highest in the deficiency group, and was inversely correlated with B12 concentration (P = 0.02, Spearman's ρ=-0.30) Other variables including the status of vascular complications, red blood cell count, the mean corpuscular volume, eGFR and serum albumin were not significantly different between the 2 groups. By partial correlation analysis, metformin use was significantly correlated with lowering of B12 and elevation of HC/B12 molar ratio, and B12 lowering was significantly correlated with elevation of HC ( Table 2) . Elevated HC was significantly correlated with presence of retinopathy but not stroke or CHD. Those with renal dysfunction were excluded in this study, but eGFR was significantly, inversely, correlated with HC. As well expected, retinopathy was significantly correlated with HbA1c and diabetes duration, and history of macroangiopathic events was significantly correlated with diabetes duration. Correlation between serum B12 concentration and plasma HC after adjustment for eGFR was stronger in the metformintreated patients (P<0.01, r =-0.48) than the non-metformin-treated patients (P =0.04, r =-0.38) (Fig. 2) .
On the basis of results of the partial correlation anal- Plus-minus values are the mean and SD. *, the differences between metformin and non-metformin groups were examined by Mann-Whitney U test for numerical variables and Fisher's exact test for categorical variables. eGFR, estimated glomerular filtration rate; CHD, coronary heart disease; RBC, red blood cell count; MCV, mean corpuscular volume; SU, sulfonylurea; DPP4i, dipeptidyl peptidase-4 inhibitor; PPI, proton pump inhibitor; H2B, H2 blocker.
Three HC values (2 in Metformin group and 1 in Non-metformin group) and 2 BMI values were missing. (<220 pmol/L), 1,500 µg/day B12 was administered po for 2.2±1.0 months with continued use of metformin. This treatment normalized serum B12 concentration in all but 2 (Fig. 3) . The mean (±SD) values were 152 (±42) and 299 (±97) pmol/L before and after the treatment, respectively (P < 0.01). Plasma HC was reduced, albeit not significantly, by the treatment: 10.4 ± 1.3 and 9.2 ± 2.5 µmol/L before and after the treatment, respectively (N = 5, P = 0.22).
Discussion
As reported previously [1] [2] [3] [4] [5] 17] , serum B12 concentration was significantly lower in the metformin-treated patients than in the non-metformin-treated patients and the dosage of metformin was inversely correlated with B12 levels. The degree of B12 deficiency in metformysis, multivariate logistic regression analysis [16] was performed to know the quantitative relation of metformin use to hyperhomocysteinemia and elevated HC to retinopathy. Twenty-one of the 46 (46%) and 13 of the 38 (34%) patients had hyperhomocysteinemia (≥10 µmol/L), in the metformin and non-metformin groups, respectively, and metformin use was independently related to hyperhomocysteinemia (OR 2.84, Table 3 , Model 1). However, the significant relation between metformin use and hyperhomocysteinemia disappeared when B12 was entered as a covariate (Table 3 , Model 2). One micromolar increase of HC was related to retinopathy with OR being 1.26 (95%CI 1.04-1.52, P = 0.02) after adjustment for HbA1c and diabetes duration.
Treatment of metformin-induced B12 deficiency
In 10 metformin-treated patients with lowered B12 Multivariate logistic regression analysis was performed with metformin use and eGFR as independent variables in Model 1, and additionally B12 in Model 2. eGFR, estimated glomerular filtration rate; OR, odds ratio; CI, confidence interval. Plasma homocysteine concentration ≥10 µmol/L was defined as hyperhomocysteinemia [9, 14] . and homocysteine values were log transformed to obtain normal distribution. After adjustment for eGFR, age, duration of diabetes and HbA1c, serum B12 concentration was significantly correlated with HC in both the metformin-treated patients (P <0.01, r = -0.48) and the nonmetformin-treated patients (P = 0.04, r = -0.38). The regression line for the metformin users was y = -0.30· x + 1.74 (the solid line) and the regression line for the non-metformin users was y = -0.18· x + 1.42 (the broken line), where y and x denote logHC and logB12, respectively. The intercept and the slope of the regression line were not significantly different between the two groups.
Therefore, we tried a large dose of B12 supplementation without discontinuation of metformin, which restored normal serum B12 concentration in the vast majority of the B12-deficient patients. A dosage smaller than 1,500 µg may have been sufficient. In view of the established benefits of metformin over other OHA in T2DM [12] , simple B12 supplementation without discontinuation of metformin was thought to be a better option than switching from metformin to another OHA. There were limitations in this study. The correlation between metformin dosage and B12 was an observational but not an interventional finding. The number of patients was rather small, and the correlation analysis was performed in the subgroups with even smaller number of patients. Due to observational nature of the analysis, a complete matching of the metformin and the non-metformin groups was not obtained. The inherent difference between the metformin users and non-metformin users may have some impact on B12 and HC levels. Also, the duration of metformin treatement was not very long.
In conclusion, we found significant independent relationship between 1) metformin use and B12 lowering, 2) B12 lowering and elevation of HC, and 3) elevation of HC and retinopathy. Simple B12 supplementation sufficed to correct the B12 deficiency associated with metformin use. It is advisable to measure serum B12 in patients on long-term metformin therapy especially if the dosage is >1,200 mg. A large scale prospective study looking at metformin, B12, HC and retinopathy is warranted.
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in-treated patients was comparable to that of the patients with gastrectomy [18] , which was worrisome. In the previous studies, the mean serum B12 concentration in the Japanese control subjects was reported to be 369 pmol/L [18] , or 401 pmol/L in men and 472 pmol/L in women [19] . These values were higher than those obtained in the patients with diabetes in our study (Table 1) . Conversely, the reported mean values for HC in the Japanese general population, 6.7 -8.3 µmol/L [14, 18, 20] , were lower than in the patients with diabetes (Table 1) . Taken together, the relationships between diabetes, metformin, B12 and HC may be interpreted as follows. Serum B12 may well be depressed in patients with diabetes [21] even in the absence of metformin use, and it is further lowered by metformin in a dose-dependent manner. This is a direct effect of the drug. HC is elevated in relation to the metformin-induced lowering of B12. Thus, metformin directly lowers serum B12 while the drug is indirectly raising plasma HC via the lowering of B12. Nevertheless, one should be cautious for direct comparison of B12 and HC values in the current study and earlier studies (14, (18) (19) (20) (21) because the reference ranges may not be identical due to difference in assay methods.
With regard to the possible deleterious effects of hyperhomocysteinemia, elevation of HC was independently related to the presence of retinopathy. Rather unexpectedly, it was not significantly related to history of macroangiopathy in our patients. Our finding is compatible with the data presented by recent studies which inferred that elevated HC was a risk factor for retinopathy [11, 22, 23] . Nevertheless, it should be noted that plasma HC concentration was only marginally higher (P =0.05) in the metformin users than the non-metformin users and prevalence of retinopathy was not significantly different between the two groups. In this study, we confirmed an inverse correlation between GFR and HC among subjects with normal renal function [24, 25] .
The management of B12 deficiency in metformintreated patients has not been established [5, 6] . A relatively small dose of B12 supplementation was not protective against metformin-induced B12 deficiency [4] .
